EMA’s safety committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that the risks of the medicine outweigh its benefits.
source https://www.pharmatutor.org/pharma-news/2020/ema-review-of-picato-concludes-medicines-risks-outweigh-its-benefits
No comments:
Post a Comment